Antisense modulation of GCCR expression
US9567587B2 · kind B2 · utility
6Cited by
13References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 24, 2014 |
| Grant date | Feb 14, 2017 |
| Priority date | — |
| Expiry date | Oct 24, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3525
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.